Navigation Links
CytRx Reports Promising Data from Its Open-Label Extension Clinical,Trial of Arimoclomol in ALS

ear with a four-fold arimoclomol dose increase, subject to FDA clearance.

"We are encouraged by the favorable results of this open-label trial, which make us even more eager to proceed at an even higher dose level in further clinical testing," stated CytRx's President and CEO Steven A. Kriegsman. "The comparison of these clinical results with historical data suggests a trend toward clinical improvement. Our Phase IIb efficacy study will be placebo-controlled and is planned to include a larger number of volunteers, treated for a longer period of time with a four-fold higher dose than that used in the open-label clinical trial."

The open-label extension clinical trial was initiated in February 2006 as ALS volunteers completing CytRx's placebo-controlled, double-blind, dose-ranging Phase IIa clinical trial were provided the opportunity to receive arimoclomol treatment for up to an additional six months. A total of 69 patients were treated in the open-label arimoclomol trial for six months, while the historical control followed 99 subjects for 12 months.

In the open-label trial, arimoclomol treatment was demonstrated to be safe as indicated by the lack of clinically-significant changes in vital signs and laboratory values, compared to baseline values. Arimoclomol was also well-tolerated with a total drop-out rate of 11.6%, or an average of 1.3% per month, during the six-month trial. This compares favorably with the historical control drop-out rate of 33.3%, or an average of 2.75% per month, for the 12-month trial.

CytRx's planned Phase IIb clinical trial is currently expected to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites treated for nine months. The trial is expected to be completed approximately 18 months after enrollment begins.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therap
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:8/22/2014)... Aug. 22, 2014 /CNW/ - On Aug. 20, at ... the Canadian Medical Association (CMA) voted on and approved ... material, including medicinal cannabis. Bedrocan Cannabis Corp., a leading ... the CMA motion. The CMA is quite ... associated with smoking any plant material, including medicinal cannabis. ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... COLORADO SPRINGS, Colo. , Aug. 22, 2014 ... Company specializing in cannabis formulation-based drug development and ... of UFCM iCare,s third international medical cannabis conference ... Strasbourg, France , on October ... experts with other stakeholders, such as researchers, health ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3
... 22, 2011 ResearchDx announced today the official ... CDO. Recent FDA initiatives, such ... Co-Development Concept Paper, have spurred biopharmaceutical companies, interest ... companion diagnostics. The traditional Contract Research Organization (CRO), ...
... OMER ) today announced that its exclusive license to ... been amended to include addiction and compulsive disorders in the ... Company,s discovery of a previously unknown link between PDE7 and ... it also is the first to link PDE7 to any ...
Cached Medicine Technology:ResearchDx Launches Contract Diagnostics Organization (CDO) 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 2Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 3Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo 4
(Date:8/22/2014)... 2014 Mi40x , the latest guide ... show people how they can use a simple 4-minute trick ... matter of weeks has caught the attention of Shane Michaels, ... of the most well-known bodybuilders in the industry, and if ... today, that in itself is a testament to how effective ...
(Date:8/22/2014)... Paying tuition and other related educational expenses ... for four nurse educators pursuing advanced degrees, thanks to ... Foundation for Nursing Education . This year’s recipients – ... than in 2013, thanks to these named NLN Foundation ... Marcil Endowment Funds, both donated by Kathy Mershon; the ...
(Date:8/22/2014)... 2014 Mueller Sports Medicine is excited ... exciting new product that provides non-drug instant relief for ... while you heal. The package includes 7 days of ... technology – it is not kinesiology tape. It’s made ... System for Plantar Fasciitis is a breakthrough in ...
(Date:8/22/2014)... West Orange, NJ. August 22, 2014. A ... shows that persons with multiple sclerosis (MS) may ... cognitive rehabilitation. The study was epublished ahead of ... (Yael Goverover, Helen Genova, Hali Griswold, Nancy D. ... awareness in persons with multiple sclerosis doi: 10.3233/NRE-141113). ...
(Date:8/22/2014)... Menstrual leaks risk stains and embarrassment, ... decided that there needed to be a better way ... producible in design variations, the Safety Net optimizes protection ... avoids embarrassment and promotes peace of mind. The pad ... The original design was submitted to the Fort Lauderdale ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), announces ... ), "We have leased, fitted and established ... will allow us to streamline the process,of new ... facility will house,both electronic and pharmaceutical laboratories," announced ...
... &, Presidential Election May Mean for Private Equity in 2008, Jan. ... the ... credit markets in,turmoil, the economy in a seeming slowdown and a presidential ... Outlook,Conference on January 29-30 at the Grand Hyatt in New York to ...
... men with chronic anxiety are at substantially higher risk, experts ... who suffer from chronic anxiety substantially increase their risk of ... stress has been linked to an increased risk of heart ... been identified as a risk factor also. , "There is ...
... 2 diabetes are often advised to cut out sucrose (table ... has been questioned by some researchers who suggest that moderate ... the diet of patients with diabetes. Now a new study ... It showed that patients who increased their daily sugar intake ...
... tendon grafts loaded with gene therapy may soon ... that has eluded surgeons to date. According to ... Therapy, a new graft technique may provide the ... can reorganize as it heals. Such tissue-engineering approaches ...
... Haemonetics,Corporation (NYSE: HAE ) will announce its Q3FY08 earnings on January ... Conference Call Dial-In Information (888) 802-8577 ... ID: 30405896 This call will be ... dial:, (800) 642-1687 (US & Canada) ...
Cached Medicine News:Health News:ReBuilder Medical Technologies, Inc. Expands R&D of New Products 2Health News:Private Equity's Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference 2Health News:Anxiety Raises Heart Attack Risk 2Health News:Anxiety Raises Heart Attack Risk 3Health News:Carrot cake study on sugar in type 2 diabetes 2Health News:Freeze-dried tendon implants prove effective in early studies 2Health News:Freeze-dried tendon implants prove effective in early studies 3Health News:Freeze-dried tendon implants prove effective in early studies 4Health News:Freeze-dried tendon implants prove effective in early studies 5
... combination of the Aliquoting System RSD 800A ... ACM-8). This turns out in an efficient ... laboratory. The System automates all important front-end ... via cap identification, sample quality control, decapping, ...
... The Aliquoting System RSD 800A is an ... and archiving (additional tube type identification via ... to process various sample tubes in a ... sorting areas are customized and offer high ...
... Sorting System RS 800 can sort different ... manual sorting are not necessary anymore and ... in a very timesaving and economical way ... Optionally a Tube Type Identification via Cap ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
Medicine Products: